Email Alert RSS
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2023  > 
WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology(CSCO)Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer（2023 edition）[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0342
Citation: WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology(CSCO)Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer（2023 edition）[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2023-0342
shu

Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer（2023 edition）

doi: 10.12290/xhyxzz.2023-0342

  • 1 Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, China;

  • 2 Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China;

  • 3 Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China;

  • 4 Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing 100730, China;

  • 5 Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing 100730, China

Funds:

National High Level Hospital Clinical Research Funding（2022-PUMCH-B-072）

  • Received Date: 2023-07-23
  • Accepted Date: 2023-08-02
    • Available Online: 2023-08-22
    Abstract
  • To further standardize the clinical diagnosis and treatment decisions of iodine refractory differentiated thyroid cancer (RAIR-DTC) in China, it is urgent to establish clinical diagnosis and treatment management guidelines based on evidence-based medical data to scientifically guide the diagnosis and treatment of RAIR-DTC. By referring to the World Health Organization Guidelines Development Manual and following the protocol of devising evidence-based guidelines, we will register and write the prospectus of "Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer". We will also devise and release official guidance documents. This guidelines prospectus mainly introduces the significance, purpose, target population, user population, guidelines formulation team members, collection and determination of clinical issues and outcome indicators, acquisition, evaluation, and synthesis of evidence, and generation of recommendations and other guidelines formulation methods and processes of the "Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer".
    • FullText(HTML)
  • loading
    • References(24)
  • [1] Zheng RS, Zhang SW, Zeng HM,et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Center, 2022, 2:1-9.
    [2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid, 2016,26:1-133.
    [3] 刘延晴, 林岩松. 碘难治性分化型甲状腺癌诊治策略及预后[J].中国实用外科杂志, 2019,39:216-220.
    [4] 王任飞,王勇,石峰,等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019,29:476-480.
    [5] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J]. J ClinEndocrinolMetab, 2006, 91:2892-2829.
    [6] Robin G, Michelle M, Dianne MW, et al.Clinical Practice Guidelines We Can Trust[M]. Washington (DC):National Academies Press (US),2011.
    [7] Brożek JL, Akl EA, Alonso CP, et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines[J]. Allergy, 2009, 64:669-677.
    [8] Howard B, Mark H, Holger JS, et al. GRADE guidelines:3. Rating the quality of evidence[J]. JClinEpidemiol, 2011, 64:401-406.
    [9] 拜争刚, 刘少堃, 黄崇斐, 等.定性系统评价证据分级工具-CERQual简介[J].中国循证医学杂志, 2015,15:1465-1470.
    [10] Melissa CB, Michelle EK, George PB, et al. AGREE II:advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182:E839-E842.
    [11] 张方圆, 沈傲梅, 马婷,等.中国癌症症状管理实践指南计划书[J].护理研究, 2018,32:8-12.
    [12] Guyatt GH, Oxman AD, Vist GE, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ, 2008, 336:924-926.
    [13] Guyatt GH,Oxman AD, Kunz R, et al. GRADE指南:Ⅱ.构建问题、确定重要结果[J]. 中国循证医学杂志, 2011,11:446-450.
    [14] Beverley JS, Barnaby CR, George W, et al.AMSTAR 2:a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358:j4008.
    [15] 熊俊,陈日新.系统评价/Meta分析方法学质量的评价工具AMSTAR[J].中国循证医学杂志,2011,11:1084-1089.
    [16] Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care:the RIGHT statement[J]. Ann Intern Med, 2017, 166:128-132.
    [17] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial[J]. Lancet. 2014, 384:319-328.
    [18] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med,2015,372:621-630.
    [19] Chi Y, Gao M, Zhang Y, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma:A randomized, double-blind, multicenter phase II trial[J]. Ann Oncol,2020, 31:S1347.
    [20] Lin YS, Qin SK,Yang H, et al. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer[J].Clin Cancer Res, 2023, 29:2791-2799.
    [21] Lin Y, Qin S, Li Z, et al. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer:The REALITY Randomized Clinical Trial[J]. JAMA oncol, 2021, 8:242-250.
    [22] Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer:A Multicenter, Open-Label, Phase II Trial[J]. Thyroid, 2020, 30:1245-1253.
    [23] Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer:Updated results from the phase 3 COSMIC-311 trial[J]. Cancer,2022,128:4203-4212.
    [24] Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks:a systematic and transparent approach to making well informed healthcare choices. 2:Clinical practice guidelines[J]. BMJ, 2016, 353:i2089.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (45) PDF downloads(34) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return